-+ 0.00%
-+ 0.00%
-+ 0.00%

X4 Pharmaceuticals Reports $240 Million Financing and Shifts Focus to Phase 3 Chronic Neutropenia Trial

Reuters·11/05/2025 12:00:23

Please log in to view news